The “up-and-coming diet drug” Viking (VKTX.US) drug enters the late stages of development, and the “Nolie” stock price fell in shock
As the Viking diet pill entered the later stages of clinical trials, Eli Lilly and Novo Nordisk stock prices declined.
Viking Sends Lilly, Novo Lower as Obesity Drug Enters Late-stage Program
Analyzing BioMarin's Position Amid Pfizer's Emergent Gene Therapy and Projected Market Impact
Pfizer (PFE) Gains 7.3% in 2024 on Its Weigh-Loss Drug Pipeline
Beware, Wegovy -- Pfizer Is Working on a Competitor
Pfizer Reports Positive Data From Trial of Gene Therapy for Haemophilia A
Ebere : This stock is going down this early morning.